Phosphodiesterase-4 inhibition in COPD

The Lancet

Volumn 374, Issue 9691, 2009, Pages 665-667

  O'Byrne, Paul M ^a   Gauvreau, Gail ^a  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CILOMILAST; CORTICOSTEROID; CYCLIC AMP; MUSCARINIC RECEPTOR BLOCKING AGENT; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IV; PLACEBO; ROFLUMILAST; SALMETEROL; TIOTROPIUM BROMIDE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG TARGETING; ENZYME INHIBITION; ENZYME METABOLISM; EOSINOPHIL; HEADACHE; HUMAN; LUNG FUNCTION; MACROPHAGE; MORBIDITY; NAUSEA; NEUTROPHIL; PNEUMONIA; POST HOC ANALYSIS; PRIORITY JOURNAL; SIDE EFFECT; SMOKING; WEIGHT REDUCTION;

EID: 69149095164     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)61538-5     Document Type: Note

References (15)

1. Boswell-Smith V., Spina D., and Page C.P. Phosphodiesterase inhibitors. Br J Pharmacol 147 (2006) S252-S257
2. Aversa A., Bruzziches R., Pili M., and Spera G. Phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction. Curr Pharm Des 12 (2006) 3467-3484
3. Jones N.A., Boswell-Smith V., Lever R., and Page C.P. The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro. Pulm Pharmacol Ther 18 (2005) 93-101
4. Grootendorst D.C., Gauw S.A., Verhoosel R.M., et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 62 (2007) 1081-1087
5. Hidi R., Timmermans S., Liu E., et al. Phosphodiesterase and cyclic adenosine monophosphate-dependent inhibition of T-lymphocyte chemotaxis. Eur Respir J 15 (2000) 342-349
6. Rabe K.F., Bateman E.D., O'Donnell D., Witte S., Bredenbröker D., and Bethke T.D. Roflumilast-an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 366 (2005) 563-571
7. Calverley P.M., Sanchez-Toril F., McIvor A., Teichmann P., Bredenbroeker D., and Fabbri L.M. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 176 (2007) 154-161
8. Compton C.H., Gubb J., Nieman R., et al., for the International Study Group. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet 358 (2001) 265-270
9. Rennard S.I., Schachter N., Strek M., Rickard K., and Amit O. Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. Chest 129 (2006) 56-66
10. Rabe K.F., Hurd S., Anzueto A., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 176 (2007) 532-555
11. Calverley P., Rabe K.F., Goehring U.-M., Kristiansen S., Fabbri L.M., Martinez F.J., and for the M2-124 and M2-125 study groups. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 374 (2009) 685-694
12. Fabbri L.M., Calverley P., Izquierdo-Alonso J.L., et al., for the M2-127 and M2-128 study groups. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 374 (2009) 695-703
13. Ernst P., Gonzalez A.V., Brassard P., and Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 176 (2007) 162-166
14. Calverley P.M., Anderson J.A., Celli B., et al., for the TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356 (2007) 775-789
15. Tashkin D.P., Celli B., Senn S., et al., for the UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359 (2008) 1543-1554